NMT1 and cancer: More importantly, PCLX-001 produces dose-dependent tumor regression and complete tumor regressions in two of three lymphoma murine xenograft models establishing an initial proof-of-concept for NMT inhibitors as cancer therapeutics and supporting its ongoing preclinical development.